EXPEDEON
DGAP-News: SYGNIS AG / Key word(s): Contract PRESS RELEASE SYGNIS AG extends OEM agreement with leading global research tools provider - This OEM customer agreement will generate revenues in excess of EUR 800,000 per annum, an increase of 35% in contract value - Provides customers with improved access to research tools through worldwide sales and distribution channels - Demonstrates strong organic growth opportunities from existing product lines
The new two-year rolling contract is expected to grow SYGNIS' revenues through this customer channel by 35% per annum, to over EUR 800,000, resulting from increased access to new product lines and the extension of the scope of the Company's long term commercial arrangements. SYGNIS is also in late stage negotiations with the partner organisation for supply and licensing agreements, which will see Expedeon's Lightning-Link(R) technology embedded into the partner's commercially available research assays, thereby securing a minimum five-year revenue stream from royalties and license fees which will contribute a further 2-4% to SYGNIS' revenue. Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said: "The continuation and expansion of this OEM agreement with a valued partner underlines the importance of the Expedeon products to the life sciences industry. The extended contract offers the opportunity to drive sales revenue growth, whilst providing customers with improved access to innovative research tools via our partner's worldwide sales and distribution channels. This agreement also underscores the significant organic growth opportunities available within our product portfolio." For further information, please contact: SYGNIS AG ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=UKCVGUPMWB Document title: OEM_Eng
21.02.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | SYGNIS AG |
| Waldhofer Str. 102 | |
| 69123 Heidelberg | |
| Germany | |
| Phone: | +49 (0) 6221 3540 125 |
| Fax: | +49 (0) 6221 3540 127 |
| E-mail: | investors@sygnis.com |
| Internet: | www.sygnis.com |
| ISIN: | DE000A1RFM03 |
| WKN: | A1RFM0 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |
656139 21.02.2018
